Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Samsung Bioepis to sell biosimilar therapies in Europe

Biogen Idec and Samsung Bioepis to sell biosimilar therapies in Europe

17th December 2013

Biogen Idec has expanded its partnership with Samsung Bioepis after exercising its right to commercialise anti-TNF biosimilar product candidates in Europe.

The companies will work together to sell biosimilars for widely-used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease in the EU, where a strong market for biosimilars and a defined regulatory pathway already exist.

It aligns with Biogen Idec's corporate strategy of remaining focused on its core business, while leveraging its expertise in manufacturing and specialty markets to meet the growing need for biosimilar therapies.

Samsung Bioepis is a joint venture created by Samsung Biologics and Biogen Idec with the aim of developing affordable and high-quality biopharmaceutical and biosimilar products.

Tony Kingsley, executive vice-president of global commercial operations for Biogen Idec, said: "As a company that aims to make a difference in the lives of patients with serious diseases, we are excited by the potential to offer additional highly effective therapies in critical areas where there is growing demand."

This comes after Biogen Idec's new multiple sclerosis therapy Tecfidera was designated as a new active substance by the European Medicines Agency's Committee for Medicinal Products for Human Use last month.ADNFCR-8000103-ID-801673294-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.